[China Resources Double-Crane: Subsidiary Propranolol Hydrochloride Injection passed consistency evaluation] On September 23, China Resources Shuang-Crane (600062.SH) announced that the company's wholly-owned subsidiary China Resources Zizhu Pharmaceutical received the "Drug Supplementary Application Approval Notice" for Propranolol Hydrochloride Injection from the State Food and Drug Administration, which approved the addition of 2ml:2mg specifications. The drug passed the generic drug quality and efficacy consistency evaluation. This drug is suitable for controlling supraventricular tachyarrhythmia, exertional angina, etc. As of the announcement date, the company's cumulative R&D investment was 3.3384 million yuan. In 2025, the sales revenue of this drug will be 3.0622 million yuan.